{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:54:11Z","timestamp":1790650451778,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1054,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS09025"],"award-info":[{"award-number":["U01NS09025"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS110879"],"award-info":[{"award-number":["R01NS110879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13311-020-00964-w","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T15:18:52Z","timestamp":1605626332000},"page":"1393-1405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-571X","authenticated-orcid":false,"given":"Albert Y.","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schwarzschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9996","key":"10.1007\/s13311-020-00964-w_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1007\/s13311-020-00964-w_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","article-title":"Parkinson's Disease","volume":"103","author":"Reich","year":"2019","journal-title":"Med Clin North Am"},{"key":"10.1007\/s13311-020-00964-w_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin Geriatr Med"},{"key":"10.1007\/s13311-020-00964-w_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson Pandemic-A Call to Action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The Emerging Evidence of the Parkinson Pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-020-00964-w_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.parkreldis.2019.11.015","article-title":"Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics","volume":"73","author":"Senkevich","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-020-00964-w_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/bs.irn.2020.02.004","article-title":"Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk","volume":"154","author":"Thomas","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"10.1007\/s13311-020-00964-w_bib8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/mds.26421","article-title":"Neuropathology of \u03b1-synuclein propagation and braak hypothesis","volume":"31","author":"McCann","year":"2016","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib11","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson's disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib12","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson's disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JPD-202128","article-title":"Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020","volume":"10","author":"McFarthing","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-020-00964-w_bib14","doi-asserted-by":"crossref","unstructured":"Schneider SA, Hizli B, Alcalay RN. Emerging targeted therapeutics for genetic subtypes of parkinsonism [published online ahead of print, 2020 Sep 10]. Neurotherapeutics 2020;1\u201315. https:\/\/doi.org\/10.1007\/s13311-020-00920-8","DOI":"10.1007\/s13311-020-00920-8"},{"key":"10.1007\/s13311-020-00964-w_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"issue":"suppl 1","key":"10.1007\/s13311-020-00964-w_bib16","first-page":"S410","article-title":"PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease; Part 1 Week-52 results","volume":"35","author":"Pagano","year":"2020","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine versus placebo in early Parkinson disease: a randomized trial","volume":"172","author":"Parkinson Study Group STEADY-PD3 Investigators","year":"2020","journal-title":"Ann Intern Med"},{"key":"#cr-split#-10.1007\/s13311-020-00964-w_bib18.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Dec 30 -. Identifier NCT02642393. Study of Urate Elevation in Parkinson's Disease, Phase 3 (SURE-PD3)"},{"key":"#cr-split#-10.1007\/s13311-020-00964-w_bib18.2","unstructured":"2020 Jul 28 [cited 2020 Oct 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02642393"},{"key":"10.1007\/s13311-020-00964-w_bib19","unstructured":"The Cure Parkinson's Trust. The PD-STAT\/Simvastatin results [Internet]. London: The Cure Parkinson's Trust; 15 Sep 2020 [cited 2020 Oct 22]. Available from: https:\/\/www.cureparkinsons.org.uk\/news\/the-pd-statsimvastatin-study-results"},{"key":"10.1007\/s13311-020-00964-w_bib20","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1007\/s13311-020-00964-w_bib21","doi-asserted-by":"crossref","unstructured":"Simuni T, Fiske B, Merchant K et al. Nilotinib in patients with advanced Parkinsons disease: a randomized phase 2A study (NILO-PD). https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.11.20093146v1. Accessed 22 Oct 2020. Preprint.","DOI":"10.1101\/2020.05.11.20093146"},{"key":"10.1007\/s13311-020-00964-w_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib24","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1007\/s13311-020-00964-w_bib25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1007\/s13311-020-00964-w_bib26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","article-title":"The function of \u03b1-synuclein","volume":"79","author":"Bendor","year":"2013","journal-title":"Neuron"},{"key":"10.1007\/s13311-020-00964-w_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"\u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat Med"},{"key":"10.1007\/s13311-020-00964-w_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.pbr.2019.10.005","article-title":"Mechanisms of alpha-synuclein toxicity: An update and outlook","volume":"252","author":"Br\u00e1s","year":"2020","journal-title":"Prog Brain Res"},{"key":"10.1007\/s13311-020-00964-w_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target alpha-synuclein pathology","volume":"298","author":"Brundin","year":"2017","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-3-19","article-title":"In vivo silencing of alpha-synuclein using naked siRNA","volume":"3","author":"Lewis","year":"2008","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-020-00964-w_bib31","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","article-title":"The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease","volume":"5","author":"Finkelstein","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"suppl 15","key":"10.1007\/s13311-020-00964-w_bib33","doi-asserted-by":"crossref","first-page":"S4.001","DOI":"10.1212\/WNL.92.15_supplement.S4.001","article-title":"A first in human study of PBT434, a novel small molecule inhibitor of a-synuclein aggregation","volume":"92","author":"Stamler","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00964-w_bib34","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.molmed.2020.03.012","article-title":"Cell-to-Cell Transmission of Tau and \u03b1-Synuclein","volume":"26","author":"Uemura","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1007\/s13311-020-00964-w_bib35","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-020-00964-w_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"10.1007\/s13311-020-00964-w_bib37","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1007\/s13311-020-00964-w_bib38","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/brain\/awt037","article-title":"Prion-like spreading of pathological \u03b1-synuclein in brain","volume":"136","author":"Masuda-Suzukake","year":"2013","journal-title":"Brain"},{"key":"10.1007\/s13311-020-00964-w_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-020-00964-w_bib40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-020-00964-w_bib41","doi-asserted-by":"crossref","first-page":"104587","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson's disease: Current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1007\/s13311-020-00964-w_bib42","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-020-00964-w_bib43","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and Tolerability of Multiple Ascending Doses of PRX002\/RG7935, an Anti-\u03b1-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-020-00964-w_bib45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib46","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"10.1007\/s13311-020-00964-w_bib47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-020-00964-w_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-020-00964-w_bib49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-020-00964-w_bib50","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"Rejuvenation' protects neurons in mouse models of Parkinson's disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"10.1007\/s13311-020-00964-w_bib51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","article-title":"The L-type channel antagonist is neuroprotective in a mouse model of Parkinson's disease","volume":"43","author":"Ilijic","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-020-00964-w_bib52","first-page":"5780809","article-title":"Risk of Parkinson's disease in the users of antihypertensive agents: an evidence from the meta-analysis of observational studies","volume":"2016","author":"Mullapudi","year":"2016","journal-title":"J Neurodegener Dis"},{"key":"10.1007\/s13311-020-00964-w_bib53","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/mds.25639","article-title":"Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)","volume":"28","author":"Parkinson Study Group","year":"2013","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"10.1007\/s13311-020-00964-w_bib54","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","article-title":"Oxidative stress in Parkinson's disease","volume":"53","author":"Jenner","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1474-4422(07)70327-7","article-title":"Mitochondria in the aetiology and pathogenesis of Parkinson's disease","volume":"7","author":"Schapira","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm.3983","article-title":"Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes","volume":"22","author":"Wang","year":"2016","journal-title":"Nat Med"},{"key":"10.1007\/s13311-020-00964-w_bib57","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","article-title":"Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease","volume":"328","author":"Parkinson Study Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-020-00964-w_bib58","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Parkinson Study Group QE3 Investigators","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13024-016-0090-7","article-title":"Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation","volume":"11","author":"Pinto","year":"2016","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-020-00964-w_bib60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","article-title":"Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial","volume":"14","author":"NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.expneurol.2017.06.017","article-title":"Targeting urate to reduce oxidative stress in Parkinson disease","volume":"298","author":"Crotty","year":"2017","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib62","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/aje\/kwm127","article-title":"Plasma urate and risk of Parkinson's disease","volume":"166","author":"Weisskopf","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1007\/s13311-020-00964-w_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0317167100012981","article-title":"Serum urate and the risk of Parkinson's disease: results from a meta-analysis","volume":"40","author":"Shen","year":"2013","journal-title":"Can J Neurol Sci"},{"key":"10.1007\/s13311-020-00964-w_bib64","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archneur.2008.65.6.nct70003","article-title":"Serum urate as a predictor of clinical and radiographic progression in Parkinson disease","volume":"65","author":"Schwarzschild","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib65","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archneurol.2009.247","article-title":"Urate as a predictor of the rate of clinical decline in Parkinson disease","volume":"66","author":"Ascherio","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","article-title":"Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial","volume":"71","author":"Parkinson Study Group SURE-PD Investigators","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib67","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cpt.1548","article-title":"N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease","volume":"106","author":"Monti","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s13311-020-00964-w_bib68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3233\/JPD-171203","article-title":"Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress","volume":"7","author":"Carroll","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-020-00964-w_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","article-title":"Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice","volume":"1037","author":"Selley","year":"2005","journal-title":"Brain Res"},{"key":"10.1007\/s13311-020-00964-w_bib70","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1523\/JNEUROSCI.4144-09.2009","article-title":"Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease","volume":"29","author":"Ghosh","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-020-00964-w_bib71","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.27275","article-title":"Iron as a therapeutic target for Parkinson's disease","volume":"33","author":"Moreau","year":"2018","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuint.2017.01.004","article-title":"Ferroptosis and cell death mechanisms in Parkinson's disease","volume":"104","author":"Guiney","year":"2017","journal-title":"Neurochem Int"},{"key":"10.1007\/s13311-020-00964-w_bib73","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson's disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1007\/s13311-020-00964-w_bib74","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease","volume":"7","author":"Martin-Bastida","year":"2017","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-020-00964-w_bib75","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1007\/s13311-020-00964-w_bib76","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson's disease: A new target for disease modification?","volume":"145-146","author":"Athauda","year":"2016","journal-title":"Prog Neurobiol"},{"key":"10.1007\/s13311-020-00964-w_bib77","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","article-title":"Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study","volume":"91","author":"De Pablo-Fernandez","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00964-w_bib78","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1007\/s13311-020-00964-w_bib79","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson's disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1007\/s13311-020-00964-w_bib80","doi-asserted-by":"crossref","first-page":"e85781","DOI":"10.1371\/journal.pone.0085781","article-title":"Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies","volume":"9","author":"Lu","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-020-00964-w_bib81","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/mds.23855","article-title":"Obesity, diabetes, and risk of Parkinson's disease","volume":"26","author":"Palacios","year":"2011","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib82","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/dc10-1922","article-title":"Diabetes and risk of Parkinson's disease","volume":"34","author":"Xu","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1007\/s13311-020-00964-w_bib83","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/17460441.2013.741580","article-title":"Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1","volume":"8","author":"Parkes","year":"2013","journal-title":"Expert Opin Drug Discovery"},{"key":"10.1007\/s13311-020-00964-w_bib84","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat Med"},{"key":"10.1007\/s13311-020-00964-w_bib85","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-020-00964-w_bib86","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JPD-171191","article-title":"c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential","volume":"7","author":"Brahmachari","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-020-00964-w_bib87","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1172\/JCI85456","article-title":"Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein-induced neurodegeneration","volume":"126","author":"Brahmachari","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-020-00964-w_bib88","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-020-00964-w_bib89","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-020-00964-w_bib90","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3233\/JPD-160975","article-title":"Could MAO-B inhibitor withdrawal rather than nilotinib benefit explain the dopamine metabolite increase in Parkinsonian study subjects?","volume":"7","author":"Schwarzschild","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"#cr-split#-10.1007\/s13311-020-00964-w_bib91.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009 Feb 2 -. Identifier NCT00833690. Study of Urate Elevation in Parkinson's Disease (SURE-PD)"},{"key":"#cr-split#-10.1007\/s13311-020-00964-w_bib91.2","unstructured":"2014 Jun 5 [cited 2020 Oct 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00833690"},{"key":"10.1007\/s13311-020-00964-w_bib92","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/mds.24997","article-title":"Trial designs used to study neuroprotective therapy in Parkinson's disease","volume":"28","author":"Lang","year":"2013","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib93","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/mds.27055","article-title":"New perspectives on study designs for evaluating neuroprotection in Parkinson's disease","volume":"32","author":"Thibault","year":"2017","journal-title":"Mov Disord"},{"issue":"Pt B","key":"10.1007\/s13311-020-00964-w_bib94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.expneurol.2017.06.018","article-title":"Clinical approaches to the development of a neuroprotective therapy for PD","volume":"298","author":"Olanow","year":"2017","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib95","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jnc.14809","article-title":"Parkinson's disease biomarkers based on \u03b1-synuclein","volume":"150","author":"Fayyad","year":"2019","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-020-00964-w_bib96","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/mds.26547","article-title":"Imaging synucleinopathies","volume":"31","author":"Brooks","year":"2016","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib97","unstructured":"The Michael J. Fox Foundation. Michael J. Fox Foundation Announces Winners of the \u201cKen Griffin Alpha-synuclein Imaging Competition\u201d to Develop Game-Changing Tool for Parkinson's Research [Internet]. New York: The Michael J. Fox Foundation; 30 Jul 2020 [cited 2020 Oct 22]. Available from: https:\/\/www.michaeljfox.org\/publication\/michael-j-fox-foundation-announces-winners-ken-griffin-alpha-synuclein-imaging"},{"key":"10.1007\/s13311-020-00964-w_bib98","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JPD-191648","article-title":"The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease","volume":"9","author":"Stephenson","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-020-00964-w_bib99","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.0000000000000424","article-title":"Longitudinal follow-up of SWEDD subjects in the PRECEPT Study","volume":"82","author":"Marek","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00964-w_bib100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/jnnp-2014-310256","article-title":"What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies","volume":"87","author":"Erro","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-020-00964-w_bib101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/cts.12492","article-title":"Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis","volume":"11","author":"Conrado","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1007\/s13311-020-00964-w_bib102","doi-asserted-by":"crossref","unstructured":"Suwijn SR, Samim H, Eggers C, et al. Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD) [published online ahead of print, 2020 Jun 25]. J Parkinsons Dis. 2020. https:\/\/doi.org\/10.3233\/JPD-202090.","DOI":"10.3233\/JPD-202090"},{"key":"10.1007\/s13311-020-00964-w_bib103","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3233\/JPD-150685","article-title":"The Concept of Prodromal Parkinson's Disease","volume":"5","author":"Mahlknecht","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-020-00964-w_bib104","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneurol.2016.152","article-title":"Advances in markers of prodromal Parkinson disease","volume":"12","author":"Postuma","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/mds.27670","article-title":"Prodromal Parkinson's Disease: The Decade Past, the Decade to Come","volume":"34","author":"Postuma","year":"2019","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib106","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib107","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/acn3.412","article-title":"A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)","volume":"4","author":"Biglan","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-020-00964-w_bib108","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.26642","article-title":"Technology in Parkinson's disease: Challenges and opportunities","volume":"31","author":"Espay","year":"2016","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00964-w_bib109","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mds.27671","article-title":"A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies","volume":"34","author":"Espay","year":"2019","journal-title":"Mov Disord"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00964-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:03:31Z","timestamp":1761807811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1878747923012485"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00964-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00964-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}